

## AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results

February 2, 2015

WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure's corporate website at <a href="https://www.atricure.com">www.atricure.com</a>. You may also access this call through an operator by calling (866) 318-8619 for domestic callers and (617) 399-5138 for international callers at least 15 minutes prior to the call start time using participant passcode 24418587.

The webcast will be available on AtriCure's website and a telephonic replay of the call will be available through March 2, 2015. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The participant passcode is 54221769.

## About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy™ Ablation System is the first and only surgical device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip Left Atrial Appendage Management (LAAM) exclusion device is the most widely sold device worldwide that's indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33.5 million people worldwide.

Source: AtriCure, Inc.

## AtriCure, Inc.

Andy Wade, Senior Vice President and Chief Financial Officer, 513-755-4564

awade@atricure.com

or

## **Investor Relations Contact:**

Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com